Study Evaluating Safety of Etanercept in Treatment of Patients With Moderate to Severe Psoriasiswith Etanercept
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Evaluate (i) safety of etanercept in patients with moderate to severe psoriasis in Spain; (ii) the incidence of adverse events reported in these patients, and (iii) the role that age and concomitant therapy might play in the development of adverse reactions.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Informed consent signed by patients prior to study entry
18 years of age or older at screening visit
Patients with moderate to severe psoriasis
Patients who have failed conventional systemic treatment
Patients who have a contraindication to conventional systemic therapy
Patients who are intolerant to conventional systemic therapy
A negative serum pregnancy test at screening in women of childbearing potential
Able to self-inject study drug or have a designee who can do so
In the opinion of the investigator, the patient will be able to comply with the requirements of the protocol